R&D | October 29, 2025
Orion secures license to Abzena’s next-generation cancer antibody
The antibody was designed and developed at Abzena’s Cambridge, UK,
The antibody was designed and developed at Abzena’s Cambridge, UK,
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Subscribe To Our Newsletter & Stay Updated
